Tags

Type your tag names separated by a space and hit enter

Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials.
Br J Clin Pharmacol. 2014 Mar; 77(3):458-65.BJ

Abstract

AIM

Clinical studies have shown that statin use may modify the risk of kidney cancer. However, these studies yielded different results. To quantify the association between statin use and risk of kidney cancer, we performed a detailed meta-analysis of published studies regarding this subject.

METHODS

A literature search was carried out using MEDLINE, EMBASE and the Cochrane database between January 1966 and October 2012. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Fixed effect and random effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also performed.

RESULTS

A total of 12 (two randomized controlled trials, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies but no evidence of publication bias. Pooled results indicated a non-significant decrease of total kidney cancer risk among all statin users (RR = 0.92, 95% CI 0.71, 1.19). Long term statin use did not significantly affect the risk of total kidney cancer (RR = 1.01, 95% CI 0.83, 1.22). In our subgroup analyses, the results were not substantially affected by study design, confounder adjustment and gender. Furthermore, sensitivity analysis confirmed the stability of the results.

CONCLUSION

The findings of this meta-analysis suggested that there was no association between statin use and risk of kidney cancer. More studies, especially randomized controlled trials and high quality cohort studies with larger sample size and well controlled confounding factors, are needed to confirm this association in the future.

Authors+Show Affiliations

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China; Department of First Clinical Medical College, Nanjing Medical University, Nanjing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

23879311

Citation

Zhang, Xiao-long, et al. "Statin Use and Risk of Kidney Cancer: a Meta-analysis of Observational Studies and Randomized Trials." British Journal of Clinical Pharmacology, vol. 77, no. 3, 2014, pp. 458-65.
Zhang XL, Liu M, Qian J, et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J Clin Pharmacol. 2014;77(3):458-65.
Zhang, X. L., Liu, M., Qian, J., Zheng, J. H., Zhang, X. P., Guo, C. C., Geng, J., Peng, B., Che, J. P., & Wu, Y. (2014). Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. British Journal of Clinical Pharmacology, 77(3), 458-65. https://doi.org/10.1111/bcp.12210
Zhang XL, et al. Statin Use and Risk of Kidney Cancer: a Meta-analysis of Observational Studies and Randomized Trials. Br J Clin Pharmacol. 2014;77(3):458-65. PubMed PMID: 23879311.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. AU - Zhang,Xiao-long, AU - Liu,Min, AU - Qian,Jian, AU - Zheng,Jun-hua, AU - Zhang,Xiao-peng, AU - Guo,Chang-cheng, AU - Geng,Jiang, AU - Peng,Bo, AU - Che,Jian-ping, AU - Wu,Yan, PY - 2013/04/27/received PY - 2013/07/15/accepted PY - 2013/7/25/entrez PY - 2013/7/25/pubmed PY - 2014/10/28/medline KW - kidney cancer KW - meta-analysis KW - risk KW - statin SP - 458 EP - 65 JF - British journal of clinical pharmacology JO - Br J Clin Pharmacol VL - 77 IS - 3 N2 - AIM: Clinical studies have shown that statin use may modify the risk of kidney cancer. However, these studies yielded different results. To quantify the association between statin use and risk of kidney cancer, we performed a detailed meta-analysis of published studies regarding this subject. METHODS: A literature search was carried out using MEDLINE, EMBASE and the Cochrane database between January 1966 and October 2012. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Fixed effect and random effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also performed. RESULTS: A total of 12 (two randomized controlled trials, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies but no evidence of publication bias. Pooled results indicated a non-significant decrease of total kidney cancer risk among all statin users (RR = 0.92, 95% CI 0.71, 1.19). Long term statin use did not significantly affect the risk of total kidney cancer (RR = 1.01, 95% CI 0.83, 1.22). In our subgroup analyses, the results were not substantially affected by study design, confounder adjustment and gender. Furthermore, sensitivity analysis confirmed the stability of the results. CONCLUSION: The findings of this meta-analysis suggested that there was no association between statin use and risk of kidney cancer. More studies, especially randomized controlled trials and high quality cohort studies with larger sample size and well controlled confounding factors, are needed to confirm this association in the future. SN - 1365-2125 UR - https://www.unboundmedicine.com/medline/citation/23879311/Statin_use_and_risk_of_kidney_cancer:_a_meta_analysis_of_observational_studies_and_randomized_trials_ L2 - https://doi.org/10.1111/bcp.12210 DB - PRIME DP - Unbound Medicine ER -